Next generation of cancer treatment: small proteins
Life Science
Imagine there was a drug for cancer treatment with almost zero side effects. And you wouldn´t have to take your medicine every fourth hour but every third week. We're closer to developing this kind of treatment than you might think.
The next generation of tailor-made proteins for cancer treatment – small affinity proteins – have several advantages over the antibodies that dominate today's market for protein drugs. Because they are small they reach effectively into tumors. They can be used for both imaging diagnostics and for treatment of cancer. The side effects are low, and so are the manufacturing costs. And in addition to cancer, small proteins can be used to treat a variety of diseases, such as Alzheimer´s.
In the sixth episode of KTH Techtalks, we meet two researchers from KTH who are doing research on these little affinity proteins: Stefan Ståhl, professor in molecular biotechnology, and John Löfblom, associate professor at the School of Biotehnology at KTH.